logo
  

XBiotech: FDA Grants Permission To Begin Trials With XB2001 Therapy In Pancreatic Cancer

XBiotech (XBIT) said the FDA has granted permission to commence clinical trials with its drug candidate for treating patients with pancreatic cancer. The phase I/II study will evaluate the company's new drug candidate when added to the ONIVYDE/5-FU combination therapy.

XBiotech's new drug XB2001 is a naturally occurring antibody. It specifically targets a process potentially involved in the growth and spread of malignant tumors; and the drug also blocks inflammation associated with tissue injury, which may reduce toxicity associated with the chemotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
RELATED NEWS
Follow RTT